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Objectives This study sought to determine the additional clinical value of gait speed to Framingham risk score (FRS), car-
diac function, and comorbid conditions in predicting cardiovascular events in patients with ST-segment elevation
myocardial infarction.
Background There is growing evidence that gait speed is inversely associated with all-cause mortality, particularly cardiovas-
cular mortality, among the elderly.
Methods We undertook a single-center prospective observational study of gait speed in 472 patients with ST-segment
elevation myocardial infarction in Japan, between 2001 and 2008. Gait speeds were measured using a 200-m
course before discharge in all patients, and we followed up cardiovascular events, which consist of cardiovascu-
lar deaths, nonfatal myocardial infarctions, and nonfatal ischemic strokes.
Results During the 2,596 person-years of follow-up, 83 patients (17.6%) experienced cardiovascular events. Cardiovascu-
lar events increased across decreasing tertiles of gait speed (fastest tertile: n  5, 3.2%; middle tertile: n  20,
12.6%; slowest tertile, n  58, 36.7%). By multiple adjusted Cox proportional hazards analysis, gait speed was a
significant and independent predictor of cardiovascular events (hazard ratio for increasing 0.1 m/s of gait speed:
0.71, 95% confidence interval [CI]: 0.63 to 0.81, p  0.001). The addition of gait speed to the model incorporat-
ing FRS, B-type natriuretic peptide levels, and comorbidity index improved reclassification (net reclassification
index: 32.8%, 95% CI: 17.4 to 48.3, p  0.001) and the C-statistics with a reasonable global fit and calibration
(C-statistics: from 0.703 [95% CI: 0.636 to 0.763] to 0.786 [95% CI: 0.738 to 0.829]).
Conclusions Among patients with ST-segment elevation myocardial infarction, slow gait speed was significantly associated
with an increased risk of cardiovascular events. (Gait Speed for Predicting Cardiovascular Events After Myo-
cardial Infarction; NCT01484158) (J Am Coll Cardiol 2013;61:1964–72) © 2013 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.020Acute myocardial infarction is one of the leading causes of
mortality, and the risk of further cardiovascular complica-
tions, including recurrent myocardial infarction, sudden
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May 14, 2013:1964–72 Gait Speed and Cardiovascular Eventsstratification for second cardiovascular events at early stage
after acute myocardial infarction is the foundation of current
cardiovascular practices.
There is growing interest in using gait speed to assess the
functional status and motor performance of older people. Because
gait speed is easily determined, it may replace more complex
physical performance tests. Recently, gait speed has been proposed
as a new useful “vital sign” (3). Decreased gait speed is associated
with increased all-cause mortality (4,5), especially cardiovascular
mortality in the elderly (6). Atherosclerotic risk factors may also be
correlated with decreased motor performances (7,8). However, it
is unknown whether gait speed is associated with the long-term
prognosis in ST-segment elevation myocardial infarction
(STEMI) patients independent of traditional risk factors,
cardiac function, and comorbid conditions. Identifying the
subset of patients after STEMI who have poor physiological
reserves, as assessed by gait speed, may help cardiologists better
predict outcomes and provide more accurate risk assessments
to their patients.
The purpose of this study is to evaluate the prognostic
value of gait speed on long-term outcomes and to determine
the degree to which gait speed affects the variability in
survival after accounting for traditional cardiovascular risk
factors, cardiac function, and comorbid conditions in
STEMI patients successfully treated with percutaneous
coronary intervention (PCI).
Methods
Study patients. Between October 2001 and October 2008,
513 consecutive patients from the Yokohama City Univer-
sity Medical Center were recruited for this study; these
patients had undergone successful primary PCI for their
first STEMI within 12 h after symptom onset. The diag-
nosis of STEMI included continuous chest pain lasting20
min, the presence of ST-segment elevation 0.1 mV in 2
contiguous leads on the electrocardiogram, and increased
creatine kinase (more than twofold the upper limit of the
hospital’s reference range). We excluded 32 patients who
did not complete the 200-m walk test due to fatigue or
symptoms. The survival status and follow-up could not be
obtained for 9 patients. Thus, 472 patients were included in
the final analysis.
All STEMI patients who were capable of walking were
routinely included to participate in the cardiac rehabilitation
program during hospitalization according to the Japanese
Circulation Society guidelines for rehabilitation in patients
with cardiovascular disease. Exercise sessions during hospi-
talization were performed under the supervision of a phys-
ical therapist with the standardized protocol, and the
intensity was determined by the Borg scale (11 to 13). Each
session lasted approximately 1 h, beginning with a warm-up
phase of stretching for 15 to 20 min, followed by 20 to 30
min of aerobic activity using either walking in a hallway or
walking on a treadmill, and 10 min of cool down. Instruc-
tion about the exercise therapy was done by an attending vphysician at an individual, 30-
min session during hospitaliza-
tion, and exercise therapy was the
patient’s responsibility after dis-
charge. Exercise intensity was
determined by Karvonen meth-
ods (Karvonen method: target
heart rate  [(220  age)  rest
heart rate] · 0.5  rest heart
rate]) or Borg scale (11 to 13).
Exercise frequency was recom-
mended at least 30 min per day,
4 days per week.
The present study was ap-
proved by the Yokohama City
University institutional review
board and was conducted in ac-
cordance with the guidelines of
the ethics committee of our in-
stitution. Written informed con-
sent was obtained from each patient before participation.
Blood tests. Blood samples were obtained on admission at
3-h intervals during the first 24 h, daily for the next 5 days,
and then every other day until discharge. Peak levels of
creatine kinase and creatine kinase-myocardial band were
measured. The estimated glomerular filtration rate (eGFR)
was determined from the creatinine level at the time of
discharge using the prediction equation proposed by the
Japanese Society of Nephrology (9). We calculated the
Framingham risk score (FRS) for secondary prevention in
these study patients (10). We used B-type natriuretic
peptide (BNP) levels at discharge (11).
Comorbidity index. We assessed comorbid conditions us-
ing the Charlson comorbidity index, which covers 19 major
disease categories including diabetes mellitus, congestive
heart failure, cerebrovascular diseases, and cancer (12). The
Charlson comorbidity index has been reported to be a
strong prognostic factor for short-term and long-term
mortality in patients with a first-time hospitalization for
acute myocardial infarction (13).
Gait speed. Before discharge, patients took a 200-m walk,
and walking time was measured using a standard digital
stopwatch. All 200-m walk tests were performed by physical
therapists with the standardized instructions in a wide hallway
on a 50-m course in the daytime (10:00 AM to 12:00 AM and
3:00 PM to 5:00 PM), and patients were asked to walk at their
sual pace without overexerting themselves. Patients did not
at a meal or exercise vigorously within 2 h of beginning the
est. Patients were permitted to use an aid such as a cane or
walker as recommended by American Thoracic Society
uideline for a 6-min walk test (14).
ollow-up and cardiovascular events. Cardiovascular-
isease outcomes were evaluated for an average follow-up of
.5 years. The primary endpoint was the incidence of
ardiovascular events during the follow-up period: cardio-
Abbreviations
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ACE-I  angiotensin-
converting enzyme inhibitor
ARB  angiotensin-II
receptor blocker
BNP  B-type natriuretic
peptide
CI  confidence interval
eGFR  estimated
glomerular filtration rates
FRS  Framingham risk
score
HR  hazard ratio
PCI  percutaneous
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STEMI  ST-segment
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Gait Speed and Cardiovascular Events May 14, 2013:1964–72stroke. Two telephone interviewers called the patients or
their families to inquire about all hospital admissions,
cardiovascular outpatient diagnosis, and death. To verify
diagnosis, 3 physicians on the events committee indepen-
dently reviewed all medical records and death certificates for
blinded endpoint classification and assignment of incidence
dates using pre-specified criteria. If the reviewing physicians
disagreed on the event classification, they adjudicated dif-
ferences. Myocardial infarction was defined by combina-
tions of symptoms, abnormalities on the electrocardiogram,
and cardiac biomarker elevation. Ischemic stroke required
documented focal neurologic deficit and clinically relevant
brain imaging of infarction. Cardiovascular death was de-
fined as a death due to myocardial infarction, congestive
heart failure, or documented sudden death without apparent
noncardiovascular causes. For patients experiencing 1
acute event, only the first event was considered in the
analysis. To avoid observer bias, the physician ascertaining
outcomes from the medical records was blinded to the gait
speed data. The secondary endpoint was all-cause death.
Statistical analysis. Descriptive statistics were analyzed to
describe the baseline characteristics according to cardiovas-
cular events and gait speed tertiles. Continuous variables
with normal distributions were expressed as mean (SD), and
data with skewed distributions were expressed as median
(interquartile range). The differences among continuous
variables with normal distributions were analyzed using
unpaired Student t tests or 1-way analysis of variance.
ann-Whitney U test and Kruskal-Wallis test were used
for continuous variables with skewed distributions. We
compared the groups using the chi-square test. Because gait
speed was strongly related to sex in previous reports (5,6),
we decided to categorize patients into sex-dependent groups
by gait speed to maintain balanced sample sizes of men and
women before data collection and examination. We used
the following cut-off values (tertiles) derived from patients
in this study: 0.926 m/s, 0.926 to 1.070 m/s, and 1.070
m/s for men; and 0.689 m/s, 0.689 to 0.916 m/s, and
0.916 m/s for women. We used sex-dependent groups by
gait speed in Tables 1 and 2 and Figure 1, and we treated
gait speed as a sex-independent continuous variable for
other analyses.
We calculated the cumulative incidence of cardiovascular
events according to thirds of gait speed using the Kaplan-
Meier method and compared it with the log-rank test. We
used Cox proportional hazards models to estimate hazard
ratios (HRs) for cardiovascular events and 95% confidence
intervals (CIs) using univariate model and multivariate
analyses with the forward entry algorithm. We tested
interactions between variables by including interaction
terms. Models were initially adjusted for age and sex. We
then included additional covariates (height, weight, current
smoking status, hypertension, diabetes mellitus, dyslipide-
mia, BNP, FRS, comorbidity index, eGFR, Killip class, left
ventricular ejection fraction, angiotensin-converting
enzyme-inhibitors [ACE-I]/angiotensin II receptor block- aers [ARB], hydroxymethylglutaryl-CoA reductase inhibi-
tors, use of cane or walker, days in bed, days from admission
to measurement of gait speed, and number of times of
rehabilitation) in the models. We conducted post-hoc
analyses on subgroups stratified by age and sex to assess
hazard ratio of gait speed for cardiovascular events.
We confirmed the proportional hazards assumption using
Schoenfeld’s test and calculated estimates of the C-statistic
for Cox proportional hazards regression models (15–17).
We also examined whether the addition of various combi-
nations (FRS, BNP, comorbidity index, and gait speed)
improved the discriminatory power of the model. Using the
bootstrap percentile method (18), 95% CIs of the C-statistics
and the increment of the C-statistics were estimated.
The calibration of the Cox regression models was as-
sessed by the Grønnesby and Borgan calibration test (19),
which compares the actual and expected number of events
within 5 groups that have been developed by partitioning
the data based on the estimated risk score (x’). We
erformed likelihood ratio tests to evaluate whether the
lobal model fit improved after the addition of gait speed.
e also evaluated the incremental effect of adding gait
peed to the FRS, BNP, and comorbidity index for predict-
ng cardiovascular events with the use of the net reclassifi-
ation index (20). For the assessment of reclassification
mprovement, we defined 3 risk categories on the basis of
he FRS plus BNP plus comorbidity index: low risk 10%,
ntermediate risk 10% to 20%, and high risk 20%.
Statistical significance was defined as p  0.05 with
-tailed tests. All analyses were performed using PASW 18
or Windows (SPSS Inc., Tokyo, Japan) and SAS pro-
ram for Windows, release 9.2 (SAS Institute Inc., Cary,
orth Carolina).
esults
uring a mean follow-up of 5.5  2.2 years, corresponding
o 2,596 person-years, 83 (17.6%) patients experienced
ardiovascular events (n 34, cardiovascular death; n 24,
onfatal myocardial infarction; n  25, nonfatal ischemic
troke). Noncardiovascular death was observed in 30 pa-
ients. Among 32 patients who were excluded because of an
ncomplete 200-m walk test, 18 (56.3%) had cardiovascular
vents and 19 (59.4%) had all-cause deaths (n  16,
ardiovascular death; n 3, noncardiovascular death; n 1,
onfatal myocardial infarction, and n 1, nonfatal ischemic
troke).
Table 1 describes the baseline clinical characteristics by
ardiovascular events status and gait speed tertiles. Patients
ho had cardiovascular events during follow-up were sig-
ificantly older and had a lower height, a lower body mass
ndex, lower eGFR, higher BNP, lower left ventricular
jection fraction, and higher comorbidity index and were
ore likely to have diabetes mellitus, FRS 12, and Killip
lassification 2. The percentage of smokers was lower
mong patients with cardiovascular events than among
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May 14, 2013:1964–72 Gait Speed and Cardiovascular Eventspatients without events. There were no significant differ-
ences in peak creatine kinase level, anterior myocardial
infarction, cardiogenic shock, stent implantation, multives-
sel coronary artery disease, and medications between the 2
groups according to cardiovascular events. Gait speed was
significantly slower in patients with cardiovascular events,
and slow gait speed was correlated with old age, lower
height, lower body mass index, lower eGFR, higher BNP,
Killip classification 2, lower left ventricular ejection frac-
tion, multivessel coronary artery disease, higher FRS, and
higher comorbidity index. Delayed timing and less fre-
quency of rehabilitation were associated with both higher
Baseline Clinical Characteristics of 472 Patients With ST-SegmentTable 1 Baseline Clinical Characteristics of 472 Patients With
Cardiovascular Eve
During Follow-Up
Overall
(n  472)
No
(n  389)
Y
(n 
Age, yrs 63.1 (11.8) 62.2 (11.6) 67.3
Male 388 (82.2) 323 (83.0) 65
Height, cm 163.9 (8.4) 164.3 (8.3) 162.1
Weight, kg 65.5 (12.3) 66.3 (11.8) 61.5
Body mass index, kg/m2 24.2 (3.4) 24.5 (3.3) 23.2
Current smoking 315 (66.7) 270 (69.4) 45
Hypertension 277 (58.7) 223 (57.3) 54
Diabetes mellitus 130 (27.5) 98 (25.2) 32
Dyslipidemia 277 (58.7) 230 (59.1) 47
eGFR, ml/min/1.73 m2 60.3 (15.9) 61.0 (15.4) 57.0
B-type natriuretic peptide, pg/ml 95 (47–207) 87 (42–165) 139
Anterior myocardial infarction 204 (43.2) 163 (41.9) 41
Killip class 2 34 (7.2) 23 (5.9) 11
Cardiogenic shock 17 (3.6) 14 (3.6) 3
Peak CK, 103 IU/l 2.3 (1.3–4.0) 2.2 (1.4–3.9) 2.8
Peak CK 3,000 IU/l 174 (36.9) 136 (35.0) 38
Left ventricular ejection fraction, % 53.5 (11.8) 54.1 (11.2) 50.3
Stent implantation 320 (67.8) 268 (68.9) 52
Final TIMI grade 2 462 (97.9) 381 (97.9) 81
Multivessel disease 139 (29.5) 110 (28.4) 29
Medications at discharge
Aspirin 471 (99.8) 388 (99.7) 83
HMG-CoA RI 315 (66.7) 266 (68.4) 49
Beta-blocker 270 (57.2) 226 (58.1) 44
ACE-I or ARB 404 (85.6) 339 (87.1) 65
Framingham risk score, % 9.7 (3.7) 9.6 (3.5) 10.4
Framingham risk score 12 137 (29.0) 103 (26.5) 34
Comorbidity index 2.4 (1.2) 2.3 (1.1) 2.9
Arthritis 8 (1.7) 6 (1.5) 2
Use of cane or walker 19 (4.0) 8 (2.1) 11
Days in bed 1.3 (2.2) 1.2 ( 2.0) 2.2
Admission to gait speed
measurement, days
7.1 (7.5) 6.5 (6.3) 9.8
Number of times of rehabilitation 7.4 (4.4) 7.6 (4.5) 6.1
Gait speed, m/s 0.943 (0.212) 0.981 (0.190) 0.761
Cardiovascular event 83 (17.6) 0 (0) 83
Values are mean (SD), median (IQR), or n (%). Significance was assessed by the unpaired Student
Comorbidity index was calculated using the Charlson index, which ranges from 0 to 37, with high
ACE-I angiotensin-converting enzyme inhibitor; ARB  angiotensin-II receptor blockers; BNP 
I  hydroxymethylglutaryl-CoA reductase inhibitor; IQR  interquartile range; TIMI  Thrombolyrate of cardiovascular events and slower gait speed. (Cardiovascular events increased across decreasing tertiles
of gait speed (fastest, n  5, 3.2% [95% CI: 0.4% to 6.0%];
middle, n  20, 12.6% [95% CI: 7.4% to 17.7%]; slowest,
n  58, 36.7% [95% CI: 29.2% to 44.2%]; p  0.001)
Table 2). In separate analyses for each component of
ardiovascular events, the increased risk of cardiovascular
eath, nonfatal myocardial infarction, and nonfatal isch-
mic stroke was observed with slower gait speed in
atients with STEMI (Table 2). Figure 1 depicts the
umulative risk of cardiovascular events by gait speed
ertiles. There was a significant difference in cardiovas-
ular events across stratified gait speeds (log rank, p  0.001)
ation Myocardial Infarctionegment Elevation Myocardial Infarction
p Value
Tertiles of Gait Speed
p Value
Slowest
(n  158)
Middle
(n  159)
Fastest
(n  155)
0.001 69.9 (10.8) 61.0 (11.2) 58.5 (10.4) 0.001
0.34 130 (82.3) 131 (82.4) 127 (81.9) 0.99
0.03 161.7 (7.4) 164.1 (8.7) 165.9 (7.1) 0.001
0.001 62.0 (11.4) 66.2 (12.6) 68.2 (12.3) 0.001
0.002 23.6 (3.3) 24.4 (3.3) 24.7 (3.5) 0.01
0.01 92 (58.2) 108 (67.9) 115 (74.2) 0.01
0.22 94 (59.5) 95 (59.7) 88 (56.8) 0.84
0.02 51 (32.3) 45 (28.3) 34 (21.9) 0.12
0.71 91 (57.6) 92 (57.9) 94 (60.6) 0.83
0.04 56.0 (17.4) 60.4 (14.1) 64.4 (14.9) 0.001
8) 0.001 131 (70–416) 92 (40–176) 75 (40–131) 0.001
0.22 76 (48.1) 69 (43.4) 59 (38.1) 0.20
0.03 21 (13.3) 8 (5.0) 5 (3.2) 0.001
0.99 7 (4.4) 6 (3.8) 4 (2.6) 0.67
.7) 0.23 2.5 (1.3–4.2) 2.5 (1.2–4.2) 2.0 (1.4–3.7) 0.44
0.08 62 (39.2) 62 (39.0) 50 (32.3) 0.35
0.007 50.3 (13.0) 53.8 (11.5) 56.4 (9.8) 0.001
0.30 106 (67.1) 106 (66.7) 108 (69.7) 0.83
0.69 153 (96.8) 156 (98.1) 153 (98.7) 0.50
0.24 64 (40.8) 42 (26.4) 33 (21.3) 0.001
0.99 158 (100) 159 (100) 154 (99.4) 0.36
0.12 89 (56.3) 115 (72.3) 111 (71.6) 0.003
0.40 82 (51.9) 99 (62.3) 89 (57.4) 0.18
0.06 122 (77.2) 143 (89.9) 139 (89.7) 0.001
0.08 10.6 (3.9) 9.5 (3.5) 9.1 (3.5) 0.001
0.01 59 (37.3) 43 (27.0) 35 (22.6) 0.01
0.001 2.8 (1.2) 2.3 (1.2) 2.1 (1.1) 0.001
0.64 5 (3.2) 3 (1.9) 0 (0.0) 0.09
0.001 19 (12.0) 0 (0) 0 (0) 0.001
0.001 2.0 (3.0) 1.1 (1.5) 0.9 (1.9) 0.001
0.001 9.8 (10.4) 5.9 (4.2) 5.6 (5.8) 0.001
0.004 6.3 (4.4) 6.9 (3.6) 9.0 (4.8) 0.001
) 0.001 0.718 (0.168) 0.971 (0.084) 1.142 (0.096) 0.001
— 58 (36.7) 20 (12.6) 5 (3.2) 0.001
the Mann-Whitney U test, 1-way analysis of variance, the Kruskal-Wallis test, or Fisher exact test.
s indicative of greater comorbidity burden.
natriuretic peptide; CK  creatine kinase; eGFR  estimated glomerular filtration rate; HMG-CoA
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Gait Speed and Cardiovascular Events May 14, 2013:1964–72Cox proportional hazards analysis for the prediction of
cardiovascular events. Multivariate Cox proportional haz-
ards analysis with forward entry algorithm revealed that a
higher level of BNP, discharge without ACE-I/ARB, a
higher comorbidity index, a longer stay in bed, less fre-
quency of rehabilitation, and a slower gait speed were
independent predictors of future cardiovascular events in
STEMI patients (Table 3). In post-hoc analyses, we inves-
tigated the prognostic value of gait speed by further strati-
fying groups by tertiles of age and sex. In patients of the
youngest age group, slow gait speed had no significant
prognostic value (HR for increasing 0.1 m/s of gait speed:
0.79, 95% CI: 0.61 to 1.04, p  0.09) (Fig. 2A). In the 2
lder groups, gait speed provided significant prognostic
nformation for cardiovascular events (middle age group HR
or increasing 0.1 m/s of gait speed: 0.71, 95% CI: 0.59 to
Cardiovascular Events According to Thirds of GaTable 2 Cardiovascular Events According to
Slowest
(n  158)
Total cardiovascular events 58 (36.7 [29.2 to 44.2])
Cardiovascular death 26 (16.5 [10.7 to 22.2])
Nonfatal myocardial infarction 14 (8.9 [4.4 to 13.3])
Nonfatal ischemic stroke 18 (11.4 [6.4 to 16.3])
Values are n (% [95% confidence interval]). Significance was assessed
Figure 1 Kaplan-Meier Estimates of Cumulative Incidence of C
The cut-off values defining the gait speed tertiles were 0.926 m/s, 0.926 to 1.070
0.916 m/s for women. Red line indicates slowest; green line indicates middle; blue0.84, p 0.001; oldest age group HR for increasing 0.1 m/s
of gait speed: 0.73, 95% CI: 0.64 to 0.83, p  0.001). The
prognostic value of gait speed was significant both in men
(HR for increasing 0.1 m/s of gait speed: 0.68, 95% CI:
0.62 to 0.76, p  0.001) and in women (HR for
increasing 0.1 m/s of gait speed: 0.65, 95% CI: 0.52 to
0.81, p  0.001) (Fig. 2B).
Multiple adjustment models for the prediction of car-
diovascular events, cardiovascular death, and all-cause
death. In our multiple adjustment model (see Methods),
the association between gait speed and cardiovascular events
remained significant (HR for increasing 0.1 m/s of gait
speed: 0.71, 95% CI: 0.63 to 0.81, p  0.001) (Table 4).
Similarly, gait speed was significantly associated with car-
diovascular deaths (HR for increasing 0.1 m/s of gait speed:
0.67, 95% CI: 0.55 to 0.81, p  0.001) and all-cause deaths
eedds of Gait Speed
tiles of Gait Speed
p Value
Middle
(n  159)
Fastest
(n  155)
(12.6 [7.4 to 17.7]) 5 (3.2 [0.4 to 6.0]) 0.001
(3.8 [0.8 to 6.7]) 2 (1.3 [0.5 to 3.1]) 0.001
(5.7 [2.1 to 9.3]) 1 (0.6 [0.6 to 1.9]) 0.004
(3.1 [0.4 to 5.9]) 2 (1.3 [0.5 to 3.1]) 0.001
log-rank test.
ascular Events Based on Gait Speed Tertiles
nd 1.070 m/s for men; and 0.689 m/s, 0.689 to 0.916 m/s, and
ndicates fastest.it SpThir
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May 14, 2013:1964–72 Gait Speed and Cardiovascular Events(HR for increasing 0.1 m/s of gait speed: 0.71, 95% CI: 0.62
to 0.82, p  0.001) in the multiple adjustment models
Table 4).
-statistics for Cox proportional hazards models and net
e-classification index to predict cardiovascular events.
he FRS was a significant predictor of cardiovascular events
HR for FRS 12: 1.66, 95% CI: 1.07 to 2.57, p  0.02).
irst, we estimated the C-statistic of the FRS alone (C-
tatistic: 0.595, 95% CI: 0.528 to 0.669). The incorporation
f BNP, comorbidity index, or gait speed into the FRS
roduced substantial gains in the prognostic information for
ardiovascular events. The addition of gait speed to the
RS, BNP, and comorbidity index resulted in a significant
ncrease in the C-statistic from 0.703 (95% CI: 0.636 to
.763) to 0.786 (95% CI: 0.738 to 0.829) (Table 5). We
onfirmed the proportional hazards assumptions using the
choenfeld test (p  0.61) and confirmed the calibration
or the model including all predictors using Grønnesby
Cox Proportional Hazards Analysis for Cardiovascular Events in PatTable 3 Cox Proportional Hazards Analysis for Cardiovascular E
Variable Total No.
CV Events,
n (%)
Male No 84 18 (21.4)
Yes 388 65 (16.8)
Age, per year
Height, per cm
Weight, per kg
Current smoking No 157 38 (24.2)
Yes 315 45 (14.3)
Hypertension No 195 29 (14.9)
Yes 277 54 (19.5)
Diabetes mellitus No 342 51 (14.9)
Yes 130 32 (24.6)
Dyslipidemia No 195 36 (18.5)
Yes 277 47 (17.0)
eGFR, ml/min/1.73m2 60 242 33 (13.6)
60 230 50 (21.7)
BNP, per tertile
Killip class 2 438 72 (16.4)
2 34 11 (32.4)
LVEF, per %
HMG-CoA RI at discharge No 157 34 (21.7)
Yes 315 49 (15.6)
ACE-I or ARB at discharge No 68 18 (26.5)
Yes 404 65 (16.1)
Comorbidity index, per 1
Use of cane or walker No 453 72 (15.9)
Yes 19 11 (57.9)
Days in bed, per day
Days from admission to gait speed
measurement, per day
No. times rehabilitation, per 1
Gait speed, per 0.1 m/s
Not selected indicates the forward algorithm selection did not reach the 0.20 significance level, wh
tertiles were 62.2 pg/ml, 62.2 to 144.1 pg/ml, and 144.1 pg/ml. Comorbidity index was ca
comorbidity burden.
CV  cardiovascular; HR  hazard ratio; LVEF  left ventricular ejection fraction; other abbrevind Borgan statistics (p  0.14) (19). The addition of vait speed to the model with FRS, BNP, and the
omorbidity index showed a better global fit compared
ith the model without gait speed, as evaluated by the
ikelihood ratio test (p  0.001). We examined the effect
odification of the interactions and found that only the
omorbidity index had significant interaction with gait
peed (p  0.04).
We treated BNP, comorbidity index, and gait speed as
ontinuous and reclassified risk scores for the study patients.
he resultant net reclassification index was significant by
dding gait speed to the FRS, BNP, and comorbidity index
index, 4.8% for patients with cardiovascular events, 28% for
atients without cardiovascular events, and 32.8% overall
95% CI: 17.4 to 48.3, p  0.001]) (Table 6).
iscussion
low gait speed was strongly associated with future cardio-
With ST-Segment Elevation Myocardial Infarctions in Patients With ST-Segment Elevation Myocardial Infarction
Univariate Model Multivariate Model
R 95% CI p Value HR 95% CI p Value
.00 [Reference] 1.00 [Reference]
.75 0.44–1.26 0.27 2.09 0.97–4.50 0.06
.04 1.02–1.06 0.001 Not selected
.98 0.95–1.00 0.07 1.03 0.99–1.07 0.13
.97 0.95–0.99 0.002 Not selected
.00 [Reference] 1.00 [Reference]
.47 0.31–0.73 0.001 0.62 0.38–1.01 0.06
.00 [Reference] Not selected
.33 0.85–2.09 0.21 Not selected
.00 [Reference] Not selected
.77 1.14–2.76 0.01 Not selected
.00 [Reference] Not selected
.86 0.56–1.33 0.50 Not selected
.00 [Reference] Not selected
.02 1.30–3.15 0.002 Not selected
.95 1.46–2.60 0.001 1.41 1.02–1.94 0.04
.00 [Reference] Not selected
.29 1.21–4.34 0.01 Not selected
.97 0.96–0.99 0.003 Not selected
.00 [Reference] Not selected
.89 0.57–1.38 0.60 Not selected
.00 [Reference] 1.00 [Reference]
.54 0.32–0.92 0.02 0.58 0.34–0.98 0.04
.53 1.29–1.81 0.001 1.32 1.10–1.57 0.003
.00 [Reference] Not selected
.48 2.36–8.49 0.001 Not selected
.15 1.08–1.23 0.001 1.11 1.02–1.21 0.01
.04 1.02–1.05 0.001 Not selected
.90 0.85–0.96 0.002 0.92 0.87–0.98 0.008
.71 0.65–0.77 0.001 0.73 0.65–0.82 0.001
independent variable was included into the stepwise regression model. The cut-off values of BNP
d using the Charlson index, which ranges from 0 to 37, with higher values indicative of greater
s in Tables 1 and 2.ientsvent
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Gait Speed and Cardiovascular Events May 14, 2013:1964–72ful primary PCI. The present study also revealed that the
addition of gait speed to FRS, BNP, and comorbidity index,
improved the risk stratification as evidenced by a substantial
increase in C-statistics and net reclassification index. The
model with gait speed showed good global model fit and
Figure 2 Cardiovascular Events HR of Gait Speed
Based on Age and Sex Subgroups
Hazard ratios (HR) of cardiovascular events were calculated for increasing 0.1 m/s
of gait speed in each subgroup: tertile of (A) age and (B) sex. CI  confidence
interval.
Hazard Ratio by Gait Speed in Multiple Adjusted ModelsTable 4 Hazard Ratio by Gait Speed in Multiple Adjusted Mode
Events Rate (95% CI) Unadjusted Mod
All CV events 83 17.6% (14.2%–21.0%) 0.71 (0.65–0.77) 0.69 (0.6
CV death 34 7.2% (4.9%–9.5%) 0.63 (0.55–0.72) 0.61 (0.5
All-cause death 64 13.6% (10.5%–16.6%) 0.68 (0.62–0.75) 0.68 (0.6
Hazard ratios of cardiovascular (CV) events, cardiovascular death, and all-cause death were calculat
included age, sex, height, weight, current smoking, hypertension, diabetes mellitus, and dyslipidem
LVEF, HMG-CoA RI, ACE-I/ARB, use of cane or walker, days in bed, days from admission to measur
sex, height, weight, current smoking, hypertension, dyslipidemia, comorbidity index, eGFR, BNP,
measurement of gait speed, and number of times of rehabilitation. Model 5, adjusted for variables i
RI, ACE-I/ARB, use of cane or walker, days in bed, days from admission to measurement of gait speed, a
Abbreviations as in Tables 1, 2, and 3.calibration. These findings indicated that the clinical assess-
ment of gait speed could identify the subsets of patients at
a higher risk for cardiovascular events after STEMI.
Although cardiovascular medicine has advanced, the
available therapies do not sufficiently minimize the risk of
cardiovascular events. Patients who have a history of myo-
cardial infarction are at high risk for future cardiovascular
events despite optimal reperfusion therapy (2). Many factors
can influence the prognosis of STEMI patients, including
age, sex, cardiac function, comorbidity, atherosclerotic bur-
den, and inflammation. There are currently no well-established
approaches to predicting life expectancy that incorporate
health and function; therefore, the introduction of a proper
risk stratification strategy for long-term mortality is neces-
sary. Past reports and our results demonstrated an increased
cardiovascular mortality in slow walkers (6). Gait speed, a
simple and informative parameter, is recommended as a
potentially useful clinical indicator of well-being to refine
survival estimates in clinical practice and research.
There are several possible reasons for the association of
gait speed with cardiovascular events. Low cardiovascular
fitness is a possible mechanism of the association between
increased cardiovascular events and slow gait speed. Walk-
ing places demands on multiple organ systems, including
the heart, lungs, blood vessels, and nervous and musculo-
skeletal systems, and requires energy. A slowing gait may
reflect both a high-energy cost of walking and decreased
organ system functions. The presence of comorbidities and
frailty could also cause a slowing gait. The assessment of gait
speed could be considered a simple and comprehensive
parameter because it integrates known and unknown dis-
turbances in multiple organ systems.
Smokers have been shown to have lower mortality after
acute coronary syndrome than nonsmokers (21). That has been
attributed to the younger age, lower comorbidity, more aggres-
sive treatment, and lower risk profile of the smoker (21). In
this study, smokers were significantly younger (age 60.2 
0.8 years vs. 68.9  11.7 years, p  0.001), and had lower
comorbidity (2.2 1.8 vs. 2.7 1.2, p 0.001) and faster gait
peed (0.982  0.193 m/s vs. 0.864  0.227 m/s, p  0.001)
than nonsmokers. Although smokers had fewer cardiovascular
events than nonsmokers in this study (14.3% vs. 24.2%,
Hazard Ratio (95% CI)
Model 2 Model 3 Model 4 Model 5
7) 0.69 (0.62–0.77) 0.71 (0.62–0.80) 0.71 (0.62–0.80) 0.71 (0.63-0.81)
2) 0.63 (0.53–0.75) 0.65 (0.54–0.79) 0.68 (0.55–0.83) 0.67 (0.55-0.81)
7) 0.70 (0.61–0.79) 0.70 (0.61–0.80) 0.74 (0.64–0.86) 0.71 (0.62-0.82)
ncreasing 0.1 m/s of gait speed. Model 1, adjusted for age and sex. Model 2, adjusted for variables
el 3, adjusted for variables included Framingham risk score, height, weight, eGFR, BNP, Killip class,
of gait speed, and number of times of rehabilitation. Model 4, adjusted for variables included age,
lass, LVEF, HMG-CoA RI, ACE-I/ARB, use of cane or walker, days in bed, days from admission to
Framingham risk score, height, weight, comorbidity index, eGFR, BNP, Killip class, LVEF, HMG-CoAls
el 1
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May 14, 2013:1964–72 Gait Speed and Cardiovascular Eventsp 0.001, by log rank), smoking was not significant associated
factor of cardiovascular events after adjustment of age, risk
factors, and comorbidity index (HR: 0.76, 95% CI: 0.46 to
1.24, p  0.27).
Regarding medication at discharge, patients in the slow-
est gait speed tertile were less frequently prescribed
hydroxymethylglutaryl-CoA reductase inhibitors and ACE-
I/ARB. Patients without hydroxymethylglutaryl-CoA re-
ductase inhibitors at discharge were significantly older (65.5 
12.0 years vs. 61.9  11.6 years, p  0.002) and had lower
low-density lipoprotein cholesterol (124.8  36.5 mg/dl vs.
140.6  36.4 mg/dl, p  0.001) than patients with
hydroxymethylglutaryl-CoA reductase inhibitors. Patients
without ACE-I/ARB at discharge were significantly older
(68.5  12.9 years vs. 62.2  11.4 years, p  0.001) and
had lower eGFR (55.5  19.9 ml/min/1.73m2 vs. 61.1 
5.0 ml/min/1.73m2, p  0.007) than patients with ACE-
I/ARB. These imbalances of medications could be caused
by higher age, lower cholesterol, and lower renal function
and could confound the relationship between gait speeds and
cardiovascular outcomes. However, in the multiple adjusted
model, including hydroxymethylglutaryl-CoA reductase inhib-
itors and ACE-I/ARB, the gait speed was still a significant
predictor of cardiovascular events (Table 4).
C-Statistics for Cox Proportional Hazards Models to Predict CardioTable 5 C-Statistics for Cox Proportional Hazards Models to Pr
C-Statistic
FRS 0.595
FRS  gait speed 0.763
FRS  BNP 0.677
FRS  BNP  gait speed 0.771
FRS  comorbidity index 0.654
FRS  comorbidity index  gait speed 0.781
FRS  BNP  comorbidity index 0.703
FRS  BNP  comorbidity index  gait speed 0.786
Framingham Risk Score (FRS), B-type natriuretic peptide (BNP), comorbidity index, and gait speed w
of skewed distributions.
CI  confidence interval.
Reclassification by Additionof G it Speed to Framinghamisk Scor , BNP, and Comorbidity Index
Table 6
Reclassification y Addition
of Gait Speed to Framingham
Risk Score, BNP, and Comorbidity Index
New Risk Category by FRSBNPComorbidity IndexGait Speed
Risk Category by
FRSBNPComorbidity Index
Low
Risk
Intermediate
Risk
High
Risk
Patients with no CV events
Low risk 88 13 7
Intermediate risk 90 48 24
High risk 26 37 56
Patients with CV events
Low risk 2 6 1
Intermediate risk 5 11 12
High risk 0 10 36
According to the Framingham risk score (FRS)  B-type natriuretic peptide (BNP)  comorbidity
index, calculated in this case of cardiovascular (CV) events, low risk indicated a risk of 10%,
intermediate risk a risk of 10% to 20%, and high risk a risk of20%. The net reclassification indexm
was 28% for patients without CV events, 4.8% for those with CV events, and 32.8% overall (95%
confidence interval: 17.4 to 48.3, p  0.001).In patients of the youngest age group, slow gait speed did
not have significant prognostic value by subgroup analysis.
However, a borderline protective effect of higher gait speed
in the youngest tertile (HR: 0.79, p  0.09) may not have
reached significance because of low statistical power rather
than a true lack of effect.
The strengths of this study include the low proportion of
patients who were lost to follow-up (9 of 481). Nine
patients were lost because of change of address (n  3), a
quarrel with the hospital (n  2), and no information about
whereabouts (n  4). Of these 9 patients, 4 patients were
categorized as fastest gait speed group, 2 patients were catego-
ized as middle gait speed group, and 3 patients were
ategorized as slowest gait speed group. There was neither
ardiovascular event nor noncardiac death until loss of
ollow-up (mean follow-up duration 734 days) in these 9
atients. Even if cardiovascular events occurred in the 4
atients of the fastest gait speed group, the HR of gait speed
or cardiovascular events after adjustment of all covariates
as still significant (HR per 0.1 m/s of gait speed: 0.73, 95%
I: 0.65 to 0.84, p  0.001).
tudy limitations. Our study also has several limitations
hat may limit generalizability of the results in this study.
his is a longitudinal study and cannot assess causality and
hange of walking speed. This study was conducted with a
elatively small number of patients at a single center.
oreover, multivariate analysis may mitigate bias after
djustment of confounding factors, but unmeasured factors
such as dose of rehabilitation), which may have an impact
n gait speed, leave room for residual bias. Long-distance
alking tests may provide information beyond short-
istance walking tests. However, in many clinical settings,
he longer distance to perform the test may limit feasibility
22,23). The most common distances used in clinical
esearch fall within the 4-m to 10-m range (24). Further
tudies are needed to confirm the importance of gait speed,
easured with short walking tests, in the cardiovascular
rognosis of STEMI patients. Because we assessed exercise
apacity in only a small number of patients in this study, we
ould not compare gait speed with exercise capacity in
redicting cardiovascular events. Last, since neither routine
lar Events in STEMI PatientsCardiovascular Events in STEMI Patients
95% CI Increment in C-Statistic 95% CI
.528–0.669
.716–0.812 0.169 0.095–0.242
.609–0.744
.724–0.816 0.095 0.044–0.149
.581–0.712
.735–0.824 0.127 0.068–0.203
.636–0.763
.738–0.829 0.083 0.040–0.135
orporated as continuous variables. Natural logarithmic transformations of BNP were used becausevascuedict
0
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ere incagnetic resonance imaging nor ankle brachial index was
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Gait Speed and Cardiovascular Events May 14, 2013:1964–72performed in this study, we probably under-estimated sub-
clinical cerebrovascular diseases, cognitive impairment, ce-
rebral white matter hyperintensity, and peripheral arterial
diseases, which are associated with atherosclerosis and could
cause slower gait speed (25–28).
Conclusions
Our study indicates that slow gait speed strongly and
independently associates with the long-term risk of cardio-
vascular events in patients after STEMI. The measurement
of gait speed is a simple and effective risk assessment in
secondary prevention strategies.
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